Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs

Zodda, Donatella; Giammona, R; Schifilliti, Silvia

doi:10.3390/pharmacy6010010

Cited by 77 publications

(69 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, both agents may cause liver steatosis and are currently only in use as adjunct therapy in homozygous familial hypercholesterolemia 31,[238][239][240][241] . No data are available on cardiovascular outcomes with either lomitapide or mipomersen 242,243 .…”

Section: [H2] Inhibitors Of Vldl Productionmentioning

confidence: 99%

Lipid management in patients with chronic kidney disease

Ferro¹,

Mark²,

Kanbay³

et al. 2018

Nat Rev Nephrol

171

142

View full text Add to dashboard Cite

Glomerular filtration rate is inversely associated with cardiovascular disease independent of conventional risk factors. An increased risk of cardiovascular disease is present even at minor levels of renal impairment and the risk is highest in patients with endstage renal disease (ESRD) requiring dialysis. Renal dysfunction changes the level, composition, and quality of blood lipids in favour of a more atherogenic profile. Patients with advanced chronic kidney disease or ESRD have a characteristic lipid pattern of hypertriglyceridemia and low HDL-cholesterol levels but normal LDL-cholesterol levels. In the general population, a clear relationship exists between LDL-cholesterol, coronary heart disease and ischaemic stroke. However, in patients with ESRD, LDL-cholesterol seems to show a negative association [Au: with these outcomes?] at below average LDL-cholesterol levels and a flat or weakly positive association with mortality at higher LDL-cholesterol levels. Overall, the available data suggest that lowering of LDL-cholesterol is beneficial for prevention of major atherosclerotic events in patients with chronic kidney disease and in kidney transplant recipient but is not beneficial in patients requiring dialysis. [Au: I've moved the description of the content of your Review to the end of the introduction as per our journal style. To fully reflect the content of your article, please finish off the abstrace with a couple of sentences relating to novel lipid-lowering therapies and the need for reconsideration of the KDIGO guidelines in the light of new data. We have a limit of 200 words for this section.] [Au: I have highlighted suggestions for glossary terms throughout your manuscript with a [G]. Please provide succinct, one-sentence definitions for these specialist terms.] [H1] Introduction Guidelines regarding the management of lipids in patients with chronic kidney disease (CKD) and especially in those with end-stage renal disease (ESRD) are inconsistent in part owing to important deficiencies in the available data. [Au: Edit OK?] In 2013 KDIGO produced a comprehensive clinical practice guideline for lipid management in CKD 1. [Au: I suggest that we cite your original Table 1 (now Table 3) in the discussion of KDIGO recommendations at the end of the review so that the table is included next to this discussion in the final layout rather than in the introduction to the Review.

show abstract

Section: [H2] Inhibitors Of Vldl Productionmentioning

confidence: 99%

Lipid management in patients with chronic kidney disease

Ferro¹,

Mark²,

Kanbay³

et al. 2018

Nat Rev Nephrol

171

142

View full text Add to dashboard Cite

show abstract

“…According to Akhani, et al [6] and Nnami, et al [7] clinical complications of atherosclerosis could be diminished and life prolonged if plasma lipid levels are lowered. It has also been found that long-term, effective treatment of hyperlipidemia can decrease the occurrence of ischemic heart disease [8]. But many promising agents developed have serious side effects, especially on adrenal function.…”

Section: Introductionmentioning

confidence: 99%

The Effect of Ginger (Zingiber officinale) on Diet Induced Hyperlipidemia and Tissue Histology in Adult Female Wistar Rats: A Biochemical and Histopathological Study

Akanfe

Komolafe

Iyanda

2020

JOCAMR

View full text Add to dashboard Cite

The study is aimed at determining the atheroprotective property of ginger (Zingiber officinale) aqueous extract to rats fed with a high-fat diet. Each group consisted of 5 rats. Group 1 represent the control group and received normal rat pellets; groups 2-5 were maintained on high-fat diet for 6 weeks to establish hyperlipidemia. Groups 1, 2, 3, 4 and 5 received distilled water, distilled water, 400, 500 and 600 mg/kg (body weight) Zingiber officinale respectively for 4 weeks. Serum concentrations of triglycerides (TG), total cholesterol (TC) and high-density lipoprotein-cholesterol (HDL-C) were determined using standard biochemical methods. Histologic examination of tissues was by Hematoxylin-Eosin staining technique. Data were analyzed using Student’s t-test and P<0.05 was considered significant. A decrease in the mean concentrations of TG, TC, low-density lipoprotein (LDL-C) and increase in HDL-C concentration of each of the treatment groups (3, 4, 5) were observed when compared with that of group 2. In rats fed high-fat diet, histologic abnormalities were observed for the heart, liver, and kidney which were not adequately corrected by ginger treatment. Results suggest that at dosage levels studied, aqueous ginger extract ameliorated biochemical but not histologic consequences of the high-fat diet.

show abstract

“…Various approaches are suggested to control dyslipidemia, including diet therapy and pharmacological interventions (Ahmed, Clasen, & Donnelly, 1998;Ito, 2012). However, taking synthetic lipid-lowering medications exerts some adverse effects and often its efficacy is attenuated after prolonged use (Ghaedi, Kord-Varkaneh, Mohammadi, Askarpour, & Miraghajani, 2019;Mohammadi, Hadi, Arab, Moradi, & Rouhani, 2019;Sahebkar et al, 2016;Zodda, Giammona, & Schifilliti, 2018). Considering the limitation of the lipidlowering drugs, there is a great deal of interest in nutraceuticals that may possibly complement the pharmaceutical treatments.…”

Section: Introductionmentioning

confidence: 99%

Effects of cardamom supplementation on lipid profile: A systematic review and meta‐analysis of randomized controlled clinical trials

Shekarchizadeh-Esfahani

Arab

Ghaedi

et al. 2019

Phytotherapy Research

View full text Add to dashboard Cite

Cardiovascular disease is a highly prevalent issue worldwide and one of its main manifestations, dyslipidemia, needs more attention. Recent studies have suggested that cardamom has favorable effects beyond lipid lowering, but the result are contradictory. Our objective was to conduct a systematic review and meta‐analysis on randomized controlled trials (RCTs) that assessed the effect of cardamom on lipids. The search included PubMed, Scopus, ISI Web of Science, Google Scholar, and the Cochrane library (up to March, 2019) to identify RCTs investigating the effects of cardamom supplementation on serum lipid parameters. Weighted mean differences (WMDs) were pooled using a random‐effect model. Meta‐analysis of data from five eligible RCTs showed that cardamom supplementation did not significantly change the concentrations of total cholesterol (WMD: −6.11 mg/dl, 95% CI [−13.06, 0.83], I2 = 0.0%), low‐density lipoprotein cholesterol (WMD: −4.31 mg/dl, 95% CI [−9.75, 1.13], I2 = 0.0%), or high‐density lipoprotein cholesterol (WMD: 1.75 mg/dl, 95% CI [−1.95 to 5.46], I2 = 71.4%). However, a significant reduction was observed in serum triglyceride (TG; WMD: −20.55 mg/dl, 95% CI [−32.48, −8.63], I2 = 0.0%) levels after cardamom supplementation. Cardamom might be able to change TG, but for confirming the results, more studies exclusively on dyslipidemia patients and considering the intake of lipid lowering agents as exclusion criteria are necessary.

show abstract

Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs

Cited by 77 publications

References 79 publications

Lipid management in patients with chronic kidney disease

Lipid management in patients with chronic kidney disease

The Effect of Ginger (Zingiber officinale) on Diet Induced Hyperlipidemia and Tissue Histology in Adult Female Wistar Rats: A Biochemical and Histopathological Study

Effects of cardamom supplementation on lipid profile: A systematic review and meta‐analysis of randomized controlled clinical trials

Contact Info

Product

Resources

About